| Document |
Document Title |
|
WO/2023/217018A1 |
Provided is a compound having a structure of formula (I), which has cancer treatment activity. Further provided are a preparation method for the compound of formula (I), and a pharmaceutical composition comprising the compound.
|
|
WO/2023/217906A1 |
The present disclosure relates to compounds of Formula (I) that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventin...
|
|
WO/2023/220223A1 |
The present disclosure is directed to compounds of Formula I: and their use as anti-viral agents for inhibition of the replication of hRSV and hMPV and treatment and prophylaxis of hRSV and hMPV infection.
|
|
WO/2023/218203A1 |
The present invention relates to compounds that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical c...
|
|
WO/2023/216122A1 |
Disclosed are a singlet oxygen type photosensitizing material having aggregation-induced emission performance, and a preparation method and use therefor. The method comprises: using phenothiazine and an iodobenzene derivative as raw mate...
|
|
WO/2023/217063A1 |
The present application provides a benzo[d]isoxazole compound and use thereof. The compound has a structure represented by the following formula I. The benzo[d]isoxazole compound of the present application can induce the degradation of B...
|
|
WO/2023/216992A1 |
Provided are a cyanine-trehalose compound, a method for preparing same, and use thereof. Specifically, the compound is represented by formula I. The cyanine-trehalose compound can be used for detecting Mycobacterium tuberculosis, and fea...
|
|
WO/2023/216753A1 |
The present invention relates to an imidazopyridazine derivative, and a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Provided in the present invention are a compound as represented by formula (1)...
|
|
WO/2023/213308A1 |
The present invention provides an amide-substituted heterocyclic compound or an isomer, a solvate, a deuterated derivative or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, R4, Ⓐ, L, L1, X, X1, and Y1 are defin...
|
|
WO/2023/215482A1 |
This disclosure provides compounds of Formula (I) (e.g., (I-A) (e.g., (I-A-1), (I-A-2), or (I-A-3)), (I-B) (e.g., (I-B-1), (I-B-2), or (I-B-3)), (I-C), (I-D), (I-E) (e.g., (I-E-1), (I-E-2), or (I-E-3)), (I-Ea) (e.g., (I-Ea-1), (I-Ea-2), ...
|
|
WO/2023/213965A1 |
The present invention relates to compounds according to Formula (I) and their use as CDK8 and/or CDK19 inhibitors.
|
|
WO/2023/215756A2 |
Described are pharmaceutical compositions and method of using the compositions. The compositions described herein can be used to treat pulmonary vascular disease. The compositions described herein can include a glutaminase inhibitor agen...
|
|
WO/2023/215471A1 |
This disclosure provides compounds of Formula (I) or (II) (e.g., Formula (I-A), (I-B), or (I-C)), or a pharmaceutically acceptable salt thereof, that induce degradation of a BCL-XL protein. These compounds are useful, for example, for tr...
|
|
WO/2023/209191A1 |
The invention concerns a novel class of Prolyl oligopeptidase binding ligands, a pharmaceutical composition comprising same, the use of said ligands as medicaments, particularly, but not exclusively to promote autophagy and/or treat a di...
|
|
WO/2023/207241A1 |
The present invention relates to a halogen-substituted isoindoline compound represented by formula I below and use thereof. The compound of the present invention has significantly better anti-tumor activity, and can be prepared into an o...
|
|
WO/2023/206274A1 |
The present disclosure provides an organic electroluminescent diode and a display panel, belonging to the technical field of display. The organic electroluminescent diode comprises an anode, a luminescent layer, a hole blocking layer, an...
|
|
WO/2023/212240A1 |
The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to inhibitors of KIF18A and methods o...
|
|
WO/2023/210741A1 |
The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
|
|
WO/2023/211945A1 |
This application is directed to inhibitors of represented by the following structural formula, and methods for their use in modulating MCT in a disease or disorder, such as cancer or neurodegenerative diseases.
|
|
WO/2023/210792A1 |
The present invention addresses the problem of providing a new herbicide which has both a high safety for crops and an excellent herbicidal activity on weeds. The herbicide is for overcoming a food crisis accompanying the expected increa...
|
|
WO/2023/211938A1 |
This application is directed to modulators of MCT represented by the following structural formula (I) and methods for their use, such as to treat cancer or neurodegenerative diseases.
|
|
WO/2023/211930A1 |
The present disclosure provides dual functioning compounds, compositions, formulations, and methods for inducing or modulating an immune or inflammatory response and treating diseases or disorders (e.g., cancer, autoimmune diseases, infl...
|
|
WO/2023/211812A1 |
The present invention is related to compounds of structure (I) as mitogen-activated protein kinase (MEK) and/or ERK inhibitors. (Formula (I)). The variables are described herein.
|
|
WO/2023/207556A1 |
The present invention provides a compound as a PRMT5-MTA inhibitor, which is a compound represented by formula (A) or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate ...
|
|
WO/2023/205914A1 |
The disclosure relates to tricyclic heterocyclic derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.
|
|
WO/2023/201423A1 |
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
|
WO/2023/201421A1 |
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
|
WO/2023/205269A1 |
The present invention relates to electrochromic devices and compositions, which include a cathodic component that includes cathodic zwitterions, where an anion is covalently bonded by a divalent linking group to a pyridinium nitrogen of ...
|
|
WO/2023/205173A1 |
Described herein are compounds that are glutaminyl-peptide cyclotransferase like (QPCTL) protein modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using su...
|
|
WO/2023/202623A1 |
Provided in the present invention are a POLQ inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and use thereof in preparing a drug for preventing or...
|
|
WO/2023/205336A1 |
The present invention relates to electrochromic devices and compositions, in which the cathodic component has cationic charge and includes counter-anions, where each counter-anion of the cathodic component is an anodic component having a...
|
|
WO/2023/202582A1 |
A compound of a GPR132 regulator, a pharmaceutically acceptable salt or ester, a prodrug, a stereoisomer, a hydrate, a solvate, a crystal form, or a metabolite form thereof, as well as a preparation method therefor and medicinal use ther...
|
|
WO/2023/205465A1 |
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
|
|
WO/2023/205219A1 |
Provided herein are E2 binding PROTACS and uses thereof.
|
|
WO/2023/202502A1 |
The present invention relates to an azole-containing organic compound and use thereof. The azole-containing organic compound has a structure represented by structural formula I, , Ar1-Ar3 is one of substituted or unsubstituted C6-C30 ary...
|
|
WO/2023/205310A1 |
The present invention relates to electrochromic devices and compositions, in which the anodic component thereof includes an anodic component anion selected from at least one anodic component anion represented by the following Formulas (I...
|
|
WO/2023/202336A1 |
Provided in the present invention are the uses of an HPK1 inhibitor in preparation of drugs for preventing and/or treating human diseases or symptoms caused by pathogen infection or related to pathogen infection, and in preparation of dr...
|
|
WO/2023/202545A1 |
Provided in the present invention is the use of a diphenyl pyrazole compound represented by general formula (I) or a pesticidally acceptable salt thereof as a herbicide synergist. The compound is an inhibitor targeting GSTs in farmland w...
|
|
WO/2023/204642A1 |
Provided are: a compound of chemical formula 1, having inhibitory activity against protein kinase, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and use thereof.
|
|
WO/2023/204668A1 |
The present invention provides a novel compound and an organic light emitting device comprising same.
|
|
WO/2023/198180A1 |
The present invention relates to a novel compound of general formula (A) capable of inhibiting and inducing degradation of EGFR, and a pharmaceutical composition comprising the compound, which can be used for treating diseases associated...
|
|
WO/2023/198172A1 |
Disclosed are an oxadiazole compound having a structure of formula (I), a pharmaceutical composition comprising same, and the use thereof as an HDAC6 inhibitor.
|
|
WO/2023/200195A1 |
The present invention relates to an organic compound, which is employed for an organic layer, such as a hole transport layer or an electron block layer, of an organic light emitting diode. The organic compound according to the present in...
|
|
WO/2023/198873A1 |
The application relates to isoxazolyl-pyrazole derivatives of the general formula (I) for the treatment of diseases and conditions such as psoriasis, autoimmune thyroiditis, inflammatory bowel disease and cancer in which inverse agonism ...
|
|
WO/2023/200315A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2023/200964A1 |
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...
|
|
WO/2023/198140A1 |
The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.
|
|
WO/2023/199091A1 |
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. [Solving Means] A compound represented by the formula (I) is useful as an agent for the prophylaxis or treatment of narcolepsy.
|
|
WO/2023/196985A1 |
Disclosed herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A and A' are each independently selected from the group consisting of: (a1), (a2), (a3), (4) and (a5) and B, B', X and Y have the meani...
|
|
WO/2023/194339A1 |
The present invention relates to a crystalline form of lanifibranor having an X-ray diffraction pattern in accordance with figure 1.
|
